<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ebola Zaire vaccine (live) (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ebola Zaire vaccine (live) (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ebola Zaire vaccine (live) (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="126409" href="/d/html/126409.html" rel="external">see "Ebola Zaire vaccine (live) (United States: Availability limited to Strategic National Stockpile distribution): Drug information"</a> and <a class="drug drug_patient" data-topicid="126475" href="/d/html/126475.html" rel="external">see "Ebola Zaire vaccine (live) (United States: Availability limited to Strategic National Stockpile distribution): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F53966164"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Vaccine</span>;</li>
<li>
<span class="list-set-name">Vaccine, Live (Viral)</span></li></ul></div>
<div class="block dop drugH1Div" id="F53992494"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1439616-1a07-4c1b-b84a-fc220993e869">
<i>Zaire ebolavirus</i>, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Zaire ebolavirus</i>, prevention (immunization): </b>Children and Adolescents: IM: 1 mL as a single dose.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F53992495"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F53992496"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F54119995"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="126409" href="/d/html/126409.html" rel="external">see "Ebola Zaire vaccine (live) (United States: Availability limited to Strategic National Stockpile distribution): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eaea52f0-c94d-4831-a8b0-d00e92ea0b84">Ebola virus disease, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Ebola virus disease, prevention (immunization): IM:</b> 1 mL as a single dose.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F54119997"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F54119998"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F55003772"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Arthritis/arthralgia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Arthritis </b>and<b> arthralgia</b> (including joint pain/tenderness) have been reported. Arthralgia is usually mild to moderate intensity; however, severe arthralgia has also been observed. Arthralgia typically resolves within a week after onset, whereas arthritis typically resolves within days to weeks after onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33417593','lexi-content-ref-28081225','lexi-content-ref-28549145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33417593','lexi-content-ref-28081225','lexi-content-ref-28549145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Arthralgia: Usually in the few days following vaccination (median: 2 days; range: 0 to 42 days). Arthritis: Usually in the second week following vaccination (median: 11 days; range: 5 to 56 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33417593','lexi-content-ref-28081225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33417593','lexi-content-ref-28081225'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Arthritis:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33417593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33417593'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of arthritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33417593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33417593'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaphylaxis </b>has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33417593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33417593'])">Ref</a></span>). Immediate treatment (including epinephrine 1 mg/mL) for anaphylaxis should be available during vaccine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Immediate hypersensitivity reactions (eg, anaphylaxis) are often IgE-mediated and non–dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.2','lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.2','lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Immediate hypersensitivity reactions: Rapid; IgE-mediated reactions (eg, anaphylaxis) generally occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.2','lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.2','lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous hypersensitivity reaction to another vaccine or vaccine component (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.2'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Rash</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin rash</b> (including maculopapular rash) and <b>vesicular eruption</b> have been reported in some patients following vaccination. Since live vaccine virus has been isolated in skin vesicles in vaccinated patients up to 9 days after vaccination, rashes should be covered with a bandage until healed and contaminated bandages should be disposed of properly (ie, sealed in plastic bag prior to disposing in the trash and hands washed with soap and water) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33417593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33417593'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F53977099"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children and adolescents: 16% to 21%; adults: 13%), decreased appetite (children and adolescents: 21% to 27%; adults: 15%), diarrhea (children and adolescents: 19%), vomiting (children and adolescents: 4% to 17%; adults: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased neutrophils, lymphocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (children and adolescents: &lt;1%; adults: ≤12%), pain at injection site (children and adolescents: 26% to 52%; adults: 21% to 70%, severe: 3%), swelling at injection site (children and adolescents: 3% to 5%; adults: ≤17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (children and adolescents: 5% to 19%; adults: 17%), dizziness (children and adolescents: 8% to 17%), drowsiness (children and adolescents: 20% to 28%; adults: 26%), fatigue (19%), headache (children and adolescents: 50% to 59%; adults: 37% to 55%), irritability (children and adolescents: 1% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (children and adolescents: 3% to 16%; adults: 7% to 19%, severe: 1%; literature suggests that incidence of arthralgia, regardless of severity, may be as high as 40% [CDC/ACIP (Choi 2021)])<span class="lexi-table-link-container"> (<a aria-label="Ebola Zaire Vaccine (Live): Adverse Reaction: Arthralgia table link" class="lexi-table-link" data-table-id="lexi-content-ebola-zaire-vaccine-live-adverse-reaction-arthralgia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ebola-zaire-vaccine-live-adverse-reaction-arthralgia')">table 1</a>)</span><span class="table-link" style="display:none;">Ebola Zaire Vaccine (Live): Adverse Reaction: Arthralgia</span>, myalgia (children and adolescents: 12% to 30%; adults: 30% to 33%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ebola Zaire Vaccine (Live): Adverse Reaction: Arthralgia" frame="border" id="lexi-content-ebola-zaire-vaccine-live-adverse-reaction-arthralgia" rules="all">
<caption style="text-align:center;">
<b>Ebola Zaire Vaccine (Live): Adverse Reaction: Arthralgia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ebola Zaire Vaccine [Live])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ebola Zaire Vaccine [Live])</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">310</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">205</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">203</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">123</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">592</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">412</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,051</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">133</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">500</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">500</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: : Crying (children and adolescents: 3% to 31%; including screaming), fever (including feverishness: children and adolescents: 1% to 83%; adults: 34% to 39%;)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (children and adolescents: 5%), skin rash (4%), vesicular eruption (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (children and adolescents: 8%; adults: 8% to 10%), oral mucosa ulcer (children and adolescents: 2% to 6%; adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site pruritus (children and adolescents: 3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (5%; severe: &lt;1%; literature suggests incidence may be as high as 24%) (CDC/ACIP [Choi 2021])<span class="lexi-table-link-container"> (<a aria-label="Ebola Zaire Vaccine (Live): Adverse Reaction: Arthritis table link" class="lexi-table-link" data-table-id="lexi-content-ebola-zaire-vaccine-live-adverse-reaction-arthritis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ebola-zaire-vaccine-live-adverse-reaction-arthritis')">table 2</a>)</span><span class="table-link" style="display:none;">Ebola Zaire Vaccine (Live): Adverse Reaction: Arthritis</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ebola Zaire Vaccine (Live): Adverse Reaction: Arthritis" frame="border" id="lexi-content-ebola-zaire-vaccine-live-adverse-reaction-arthritis" rules="all">
<caption style="text-align:center;">
<b>Ebola Zaire Vaccine (Live): Adverse Reaction: Arthritis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ebola Zaire Vaccine [Live])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ebola Zaire Vaccine [Live])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,051</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">133</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Includes arthritis, monoarthritis, polyarthritis, osteoarthritis, joint swelling, or joint effusion</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Neuromuscular &amp; skeletal: Joint swelling</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Anaphylaxis (CDC/ACIP [Choi 2021])</p></div>
<div class="block coi drugH1Div" id="F53966019"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe allergic reaction (eg, anaphylaxis) to any component of the vaccine, including rice protein.</p></div>
<div class="block war drugH1Div" id="F54119988"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Rash: Maculopapular and vesicular rashes have occurred. Rash should be covered with a bandage until healed. Place contaminated bandages in a sealed plastic bag and dispose of in the trash; wash hands with soap and water after disposing of the plastic bag (CDC/ACIP [Choi 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis or tendinopathy) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Postpone administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP generally recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or nonlive) for which a person is eligible at a single visit, unless contraindications exist (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Ebola Zaire vaccine (live) has not been adequately studied in immunosuppressed patients but has been studied in a small number of individuals infected with HIV; risks and benefits should be weighed (CDC/ACIP [Choi 2021]; Kennedy 2017). In general, live vaccines should be administered ≥4 weeks prior to planned immunosuppression and avoided within 2 weeks of immunosuppression when feasible; live vaccines should not be administered for ≥3 months after immunosuppressive therapy (ACIP [Kroger 2023]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Transmission of virus: Transmission of vaccine virus is a theoretical risk; vaccine virus RNA was present in blood, saliva, urine, and fluid from skin vesicles of vaccinated adults for 7 to 20 days after vaccination. For ≥6 weeks postvaccination, vaccine recipients should not donate blood and should avoid exposing high-risk persons (ie, neonates and infants, immunocompromised persons) or livestock to their blood/bodily fluids. For 2 months postvaccination, recipients should use effective barrier contraception during any sexual contact (regardless of childbearing status or sexual orientation). For 2 weeks after vaccination, the vaccine recipient should avoid sharing needles, razors, eating utensils, cups, or toothbrushes with others and avoid open-mouth kissing; if oral sores develop following vaccination, these activities should be avoided until the sores heal (CDC/ACIP [Choi 2021]).</p></div>
<div class="block accres drugH1Div" id="F55682149"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Ervebo is not commercially available in the United States. Supplies are owned by the US federal government and are included in the Strategic National Stockpile.</p></div>
<div class="block admp drugH1Div" id="F53992497"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IM: Administer as soon as possible following thawing; discard if not used within 4 hours of thawing. Administer IM. Use proper injection technique in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). To prevent syncope-related injuries, patients should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). Cover injection site with bandage; may remove once there is no visible fluid leakage and place used bandage in sealed plastic bag and dispose of in trash. Wash hands well after disposing of plastic bag (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33417593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33417593'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p></div>
<div class="block adm drugH1Div" id="F54119999"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer IM. Use proper injection technique in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). Cover injection site with bandage; may remove once there is no visible fluid leakage and place used bandage in sealed plastic bag and dispose of in trash. Wash hands well after disposing of plastic bag (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33417593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33417593'])">Ref</a></span>). Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, patients should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>
<p style="text-indent:-2em;margin-left:2em;">For patients at risk of hemorrhage following IM injection, the vaccine should be administered IM if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F54119990"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store frozen at -80°C to -60°C (-112°F to -76°F). Protect from light. Thaw the vial at room temperature (not in the refrigerator) until no visible ice is present. Use immediately after thawing or store thawed vial refrigerated at 2°C to 8°C (35.6°F to 46.4°F) for up to 2 weeks or at room temperature (up to 25°C [77°F]) for up to 4 hours. Protect from light. Do not refreeze thawed vaccine.</p></div>
<div class="block usep drugH1Div" id="F53992491"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prevention of disease caused by <i>Zaire ebolavirus</i> (FDA approved in ages ≥12 months and adults).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Duration of protection is unknown. Protects only against <i>Z. ebolavirus</i>; does not protect against other species of <i>Ebolavirus</i> or <i>Marburgvirus</i>. Effectiveness when administered concurrently with antiviral medication, immune globulin, and/or blood or plasma transfusions is unknown.</p>
<p style="text-indent:-2em;margin-left:2em;">The Advisory Committee on Immunization Practices (ACIP) recommends preexposure vaccination for the following individuals ≥18 years of age (CDC/ACIP [Choi 2021]):</p>
<p style="text-indent:-2em;margin-left:4em;">- Persons responding to Ebola virus disease outbreak</p>
<p style="text-indent:-2em;margin-left:4em;">- Health care professionals working at a federally designated Ebola treatment center</p>
<p style="text-indent:-2em;margin-left:4em;">- Laboratory or other personnel working at a biosafety level 4 facility</p></div>
<div class="block cyt drugH1Div" id="F53978875"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F53978872"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Cladribine may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live vaccines during and for 1 month after therapy with immunosuppressive doses of corticosteroids (equivalent to prednisone &gt; 2 mg/kg or 20 mg/day in persons over 10 kg for at least 2 weeks). Give live vaccines 4 weeks prior to therapy if possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethyl Fumarate: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live). Management: Non-US labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment. US labeling states that safety and effectiveness of live vaccines administered with dimethyl fumarate has not been assessed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dupilumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebola-Directed Monoclonal Antibodies: May diminish the therapeutic effect of Ebola Zaire Vaccine (Live). Management: Wait several months (3 to 6 months, and up to 11 months) after use of Ebola-directed antibodies before administering the live Ebola Zaire vaccine. Repeat vaccination may be required if antibody therapy and vaccination cannot be adequately separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Etrasimod may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for as long as 6 to 11 months following immune globulin administration. Recommendations vary by product and immune globulin dose, see full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May diminish the therapeutic effect of Vaccines (Live).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live). Methotrexate may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose methotrexate (0.4 mg/kg/week or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses of methotrexate should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Immune Globulin (Human): May diminish the therapeutic effect of Vaccines (Live). Management: Avoid administering the measles vaccine within 4 months after administration of rabies immune globulin. Avoid administering other live vaccines within 3 months after administration of rabies immune globulin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccines-associated infection may be increased. Teplizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezepelumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tildrakizumab: May enhance the adverse/toxic effect of Vaccines (Live). The risk for contracting an infection from the vaccine may be increased. Tildrakizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tralokinumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: It is preferable to administer live vaccines simultaneously with tuberculin tests. If a live vaccine has been recently administered, the tuberculin skin test should be administered 4 to 6 weeks following the administration of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): May diminish the therapeutic effect of other Vaccines (Live). Management: Two or more injectable or nasally administered live vaccines not administered on the same day should be separated by at least 28 days (ie, 4 weeks). If not, the vaccine administered second should be repeated at least 4 week later.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55499009"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Following infection, the Ebola virus can be detected in body fluids, including vaginal secretions and semen; male to female sexual transmission has been documented. The Ebola virus vaccine contains a live attenuated virus, and there is a potential for transmission of the vaccine virus via sexual contact. Until additional data are available, it is recommended that vaccine recipients use effective barrier contraception during any sexual contact (regardless of childbearing status or sexual orientation) for 2 months after vaccination. In addition, vaccine recipients should avoid exposing high-risk persons to body fluids, including saliva (eg, from open mouth kissing), for up to 6 weeks after vaccination (CDC/ACIP [Choi 2021]).</p></div>
<div class="block pri drugH1Div" id="F54119986"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">There is limited information related to pregnancy outcomes in persons who became pregnant following vaccination with an Ebola virus vaccine (CDC/ACIP [Choi 2021]; WHO 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Following maternal infection, the Ebola virus can be detected in maternal body fluids and transmitted to the fetus. Maternal Ebola infection carries a high rate of mortality for both the fetus and the mother. Maternal Ebola virus infection may result in miscarriage, stillbirth, and maternal and/or neonatal death (Olgun 2018).</p>
<p style="text-indent:0em;margin-top:2em;">It is not known if the vaccine virus can be transmitted to others via close personal contact. Until additional data are available, vaccine recipients should avoid exposing high-risk persons (including pregnant patients) to body fluids for up to 6 weeks after vaccination (CDC/ACIP [Choi 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">In general, vaccination with live, attenuated virus vaccines is contraindicated during pregnancy (CDC/ACIP [Kroger 2023]). A decision to vaccinate a patient who is pregnant should consider the risk of exposure to Zaire ebolavirus (CDC/ACIP [Choi 2021]). In areas with an active outbreak, pregnant patients may be offered the vaccine in the context of clinical research or as part of a compassionate use protocol (WHO 2020).</p></div>
<div class="block mopp drugH1Div" id="F53992498"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for hypersensitivity reactions and syncope for 15 minutes following administration (ACIP [Kroger 2023]). Monitor for development of rash. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>
<div class="block pha drugH1Div" id="F54119992"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Provides active immunization against <i>Zaire ebolavirus.</i></p></div>
<div class="block phk drugH1Div" id="F54119993"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Duration: Unknown (CDC/ACIP [Choi 2021]).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56521992"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Zabdeno</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ervebo</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi: 10.1016/S0140-6736(18)32218-32219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ebola-zaire-vaccine-live-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28081225">
<a name="28081225"></a>Chappell KJ, Watterson D. Fighting Ebola: A Window for Vaccine Re-evaluation? <i>PLoS Pathog</i>. 2017;13(1):e1006037. doi: 10.1371/journal.ppat.1006037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ebola-zaire-vaccine-live-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/28081225/pubmed" id="28081225" target="_blank">28081225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33417593">
<a name="33417593"></a>Choi MJ, Cossaboom CM, Whitesell AN, et al. Use of Ebola vaccine: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. <i>MMWR Recomm Rep</i>. 2021;70(1):1-12. doi:10.15585/mmwr.rr7001a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ebola-zaire-vaccine-live-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/33417593/pubmed" id="33417593" target="_blank">33417593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ebola-zaire-vaccine-live-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ervebo.1">
<a name="Ervebo.1"></a>Ervebo (<i>Ebola Zaire</i> vaccine) [prescribing information]. Rahway, NJ: Merck &amp; Co Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc</i> (2003). 2013;53(1):102-103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ebola-zaire-vaccine-live-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28549145">
<a name="28549145"></a>Halperin SA, Arribas JR, Rupp R, et al; V920-012 Study Team. Six-month safety data of recombinant vesicular stomatitis virus-zaire ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. <i>J Infect Dis</i>. 2017;215(12):1789-1798. doi: 10.1093/infdis/jix189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ebola-zaire-vaccine-live-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/28549145/pubmed" id="28549145" target="_blank">28549145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29020589">
<a name="29020589"></a>Kennedy SB, Bolay F, Kieh M, et al; PREVAIL I Study Group. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. <i>N Engl J Med</i>. 2017;377(15):1438-1447. doi:10.1056/NEJMoa1614067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ebola-zaire-vaccine-live-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/29020589/pubmed" id="29020589" target="_blank">29020589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Updated 2023. Accessed April 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.2">
<a name="Kroger.2"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Updated February 10, 2023. Accessed May 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35202354">
<a name="35202354"></a>Malenfant JH, Joyce A, Choi MJ, et al. Use of ebola vaccine: expansion of recommendations of the Advisory Committee on Immunization Practices to include two additional populations - United States, 2021. <i>MMWR Morb Mortal Wkly Rep</i>. 2022;71(8):290-292. doi:10.15585/mmwr.mm7108a2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ebola-zaire-vaccine-live-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/35202354/pubmed" id="35202354" target="_blank">35202354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>NICE Clinical Guideline 183. Diagnosis and management of drug allergy in adults, children and young people. <i>Drug allergy</i>. 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29384053">
<a name="29384053"></a>Olgun NS. Viral infections in pregnancy: a focus on Ebola virus. <i>Curr Pharm Des</i>. 2018;24(9):993-998. doi:10.2174/1381612824666180130121946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ebola-zaire-vaccine-live-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/29384053/pubmed" id="29384053" target="_blank">29384053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24421306">
<a name="24421306"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ebola-zaire-vaccine-live-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/24421306/pubmed" id="24421306" target="_blank">24421306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32091684">
<a name="32091684"></a>World Health Organization (WHO). Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease [Internet]. Geneva: World Health Organization; February 2020. https://www.who.int/reproductivehealth/publications/ebola-pregnant-and-breastfeeding-women/en/
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ebola-zaire-vaccine-live-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/32091684/pubmed" id="32091684" target="_blank">32091684</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 127142 Version 60.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
